Search the Newsreel

Candel Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20.88, Implies 77% Upside

Candel Therapeutics, Inc. (CADL) has seen its average 12-month price target raised to $20.88 by analysts, up from $20.5, with individual forecasts ranging from $12 to $29. This new target suggests a potential upside of approximately 77% from its closing price on August 13. …

Equities Analysts Offer Predictions for CADL FY2028 Earnings

BofA Adjusts Price Target on Candel Therapeutics to $12 From $9

BofA has increased its price target for Candel Therapeutics (CADL) to $12, up from the previous $9. This adjustment follows several recent announcements from Candel Therapeutics, including its Q2 earnings results, the initiation of a global Phase 3 trial for a lung-cancer drug, and …

Candel Therapeutics (NASDAQ:CADL) Releases Earnings Results, Misses Expectations By $0.30 EPS

* Candel Therapeutics press release [https://seekingalpha.com/pr/20618191-candel-therapeutics-reports-second-quarter-2026-financial-results-and-recent-corporate] (CADL [https://seekingalpha.com/symbol/CADL]): Q2 GAAP EPS of -$0.52 misses by $0.29. * Cash and cash equivalents of $201.6 million, as of June 30, 2026, are expected to be sufficient to fund the Company’s current operating plan into Q1 2028, …

Candel Therapeutics (NASDAQ:CADL) Sets New 12-Month High - Here's What Happened

Candel Therapeutics (NASDAQ:CADL) recently reached a new 52-week high of $11.45, closing at approximately $11.18 on significant trading volume. Despite missing quarterly EPS expectations by $0.30 with a loss of $0.52 per share, analyst sentiment remains generally positive, holding a "Moderate Buy" consensus and …

Earnings Flash (CADL) Candel Therapeutics Posts Q2 Net Loss $0.52 a Share, vs. FactSet Est of $0.21 Loss

Candel Therapeutics (CADL) reported a Q2 net loss of $0.52 per share, which is significantly wider than the FactSet estimate of a $0.21 loss per share. The article provides this key financial update along with recent news and company profile information.

Candel Therapeutics, Inc. Q2 2026: Net income $(38.9M), EPS $(0.52) — 10-Q Summary

Candel Therapeutics, Inc. reported a widened net loss for Q2 2026, with net income at $(38.9M) and diluted EPS at $(0.52), due to continued investments in clinical programs. The company remains pre-revenue but expects its cash reserves to fund operations and trials into Q1 …

Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Candel Therapeutics announced its Q2 2026 financial results, highlighting significant progress in its clinical programs. The company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec for prostate cancer in Q4 2026 and has initiated a pivotal Phase 3 trial for NSCLC. …

Candel Therapeutics (NASDAQ: CADL) widens H1 2026 loss while boosting cash above $200M

Form 8K Candel Therapeutics Inc For: 13 August By Investing.com

This article announces that Candel Therapeutics Inc. filed a Form 8K on August 13th, as reported by Investing.com. The brief piece includes the company's stock symbol CADL and its performance for the day. No further details about the Form 8K content are provided within …

Candel Therapeutics reports Q2 2026 net loss $38.9M, cash $201.6M; plans BLA submission Q4 2026

Candel Therapeutics reported a net loss of $38.9 million for Q2 2026, with $201.6 million in cash and equivalents, expected to fund operations into Q1 2028. The company plans to submit a Biologics License Application for aglatimagene in prostate cancer in Q4 2026, highlighting …

Candel Therapeutics GAAP EPS of -$0.52 misses by $0.29

* Candel Therapeutics press release [https://seekingalpha.com/pr/20618191-candel-therapeutics-reports-second-quarter-2026-financial-results-and-recent-corporate] (CADL [https://seekingalpha.com/symbol/CADL]): Q2 GAAP EPS of -$0.52 misses by $0.29. * Cash and cash equivalents of $201.6 million, as of June 30, 2026, are expected to be sufficient to fund the Company’s current operating plan into Q1 2028, …

Candel's Prostate Therapy Candidate Shows 39% Disease-Free Survival Improvement

Candel Therapeutics announced its second-quarter 2026 financial results, reporting a net loss of $38.9 million. The company highlighted significant clinical progress, including a planned Biologics License Application (BLA) submission in Q4 2026 for aglatimagene besadenovec in prostate cancer, supported by phase 3 data showing …

Candel Therapeutics at canaccord growth conference: prostate cancer push

Candel Therapeutics (CADL) presented its viral immunotherapy pipeline at Canaccord Genuity’s 46th Annual Growth Conference, focusing on significant clinical momentum in localized prostate cancer. The company highlighted positive late-stage data for aglatimagene besadenovec in prostate cancer, aiming for a biologics license application by late …

Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow

Janus Henderson Group PLC Makes New Investment in Candel Therapeutics, Inc. $CADL

Janus Henderson Group PLC recently acquired 171,978 shares of Candel Therapeutics (NASDAQ:CADL), valued at approximately $845,000, representing a 0.23% stake in the company. Institutional investors now collectively own 13.93% of Candel Therapeutics. The stock holds a "Moderate Buy" consensus rating from analysts, with a …

Candel Therapeutics Inc (CADL) Earnings Forecast: Future EPS & Revenue Growth Estimates

Wall Street Zen Upgrades Candel Therapeutics (NASDAQ:CADL) to "Hold"

Wall Street Zen has upgraded Candel Therapeutics (NASDAQ:CADL) from a "Sell" to a "Hold" rating. This follows a similar upgrade by Zacks Research to "Hold." The company is developing oncolytic viral therapies for solid tumors, and its shares opened at $10.59, near its 52-week …

Candel Therapeutics Inc (CADL) Stock News Today

Candel Therapeutics Insider Ups Holding By 14% During Year

An insider at Candel Therapeutics increased their holdings by 14% over the past year, as reported by recent SEC filings. This significant increase in ownership by a company insider could be seen as a positive signal to investors, indicating confidence in the company's future …

Candel Therapeutics (CADL) Expected to Announce Earnings on Thursday

Candel Therapeutics to present prostate cancer data at ASTRO By Investing.com

Candel Therapeutics Inc. (NASDAQ:CADL) will present data on its aglatimagene besadenovec immunotherapy for localized prostate cancer at the 2026 American Society for Radiation Oncology Annual Meeting. The presentation will detail how quantitative digital pathology defines immune activation following the treatment. Aglatimagene besadenovec, Candel's lead …

Three New Employees Receive Candel Options at $10.01

Candel Therapeutics (Nasdaq: CADL) announced that its Board Compensation Committee granted inducement stock options to three new employees on July 31, 2026. These options allow the employees to purchase an aggregate of 30,800 shares of common stock at an exercise price of $10.01 per …

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics, Inc. announced that its Compensation Committee granted stock options to three new employees to purchase an aggregate of 30,800 shares of common stock. These inducement grants, with an exercise price of $10.01 per share, were made under the Company's 2025 Inducement Plan …

Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026

Candel Therapeutics announced that an abstract detailing extended data from its Phase 3 clinical trial of aglatimagene besadenovec in localized prostate cancer has been accepted for poster presentation at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting. The presentation, led by Dr. …

Candel Therapeutics Market Sentiment

This article analyzes the market sentiment for Candel Therapeutics (CADL) based on analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" consensus from 11 analysts with an average price target of $19, a bearish short interest of 28.7%, and a …

Candel Therapeutics webcast set for Aug. 12 Boston conference

Candel Therapeutics (Nasdaq: CADL) announced it will present at Canaccord Genuity’s 46th Annual Growth Conference in Boston, MA, on August 12, 2026, at 12 PM EDT. A live webcast will be available on the company's investor website, with a replay accessible for 90 days. …

CADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data

Candel Therapeutics' stock (CADL) rose 3% after hours following the release of positive extended follow-up data for its drug CAN-2409, which showed a significant improvement in prostate cancer-specific disease-free survival. The company plans to submit a Biologics License Application to the FDA in Q4 …

Candel Therapeutics to present cancer immunotherapy updates at Canaccord Genuity Growth Conference in August 2026

Candel Therapeutics, a clinical-stage biopharmaceutical company, announced it will present updates on its cancer immunotherapy programs at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12, 2026. The company is developing multimodal immunotherapies, including lead candidates aglatimagene besadenovec and linoserpaturev, for …

Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston

Candel Therapeutics (Nasdaq: CADL) announced it will present at Canaccord Genuity's 46th Annual Growth Conference in Boston on August 12, 2026. The company, a clinical-stage biopharmaceutical firm, focuses on developing multimodal immunotherapies for cancer. Candel Therapeutics will provide presentation details and highlight its clinical-stage …

H.C. Wainwright reiterates Candel Therapeutics stock rating at buy

H.C. Wainwright maintained a Buy rating and a $23.00 price target for Candel Therapeutics Inc. (NASDAQ:CADL), citing constructive expert opinions on their lead therapy, aglatimagene besadenovec (CAN-2409). The company has also initiated a global phase 3 trial for lung cancer and recently appointed a …

Candel Therapeutics Inc (CADL) Institutional Confidence

Candel Therapeutics Inc (CADL) shows an institutional shareholding score of 3.00, placing it 192nd out of 385 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 33.26%, a 33.22% decrease quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 65.26K shares.

Candel Therapeutics Inc (CADL) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides an overview of Candel Therapeutics Inc (CADL) regarding its dividends and stock splits. It states that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts or stock split events. The page also displays …